115 related articles for article (PubMed ID: 11822361)
1. Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody.
Iannitto E; Ammatuna E; Marino C; Cirrincione S; Greco G; Mariani G
Blood; 2002 Feb; 99(3):1096-7. PubMed ID: 11822361
[No Abstract] [Full Text] [Related]
2. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).
Jensen M; Winkler U; Manzke O; Diehl V; Engert A
Ann Hematol; 1998; 77(1-2):89-91. PubMed ID: 9760161
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rituximab in the treatment of refractory chronic lymphocytic leukemia patient with bone marrow aplasia.
Marotta G; Lenoci M; Fabbri A; Tozzi M; Lauria F
Hematol J; 2002; 3(6):299-301. PubMed ID: 12522452
[TBL] [Abstract][Full Text] [Related]
4. Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: successful treatment with rituximab.
Smolej L; Belada D; Cermanová M; Maisnar V; Lunáková E
Leuk Res; 2010 May; 34(5):e140-1. PubMed ID: 20053448
[No Abstract] [Full Text] [Related]
5. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature.
Nader K; Patel M; Ferber A
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):511-3. PubMed ID: 23726016
[No Abstract] [Full Text] [Related]
6. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
7. DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with alemtuzumab.
d'Arena G; de Filippi R; Pinto A
Leuk Lymphoma; 2007 Mar; 48(3):625-7. PubMed ID: 17454610
[No Abstract] [Full Text] [Related]
8. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.
Perz J; Topaly J; Fruehauf S; Hensel M; Ho AD
Leuk Lymphoma; 2002 Jan; 43(1):149-51. PubMed ID: 11908720
[TBL] [Abstract][Full Text] [Related]
9. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
Seipelt G; Böhme A; Koschmieder S; Hoelzer D
Ann Hematol; 2001 Mar; 80(3):170-3. PubMed ID: 11320903
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of steroid and cyclophosphamide-resistant hemolysis in chronic lymphocytic leukemia with rituximab.
Chemnitz J; Draube A; Diehl V; Wolf J
Am J Hematol; 2002 Mar; 69(3):232-3. PubMed ID: 11891815
[No Abstract] [Full Text] [Related]
11. Anti-CD20 monoclonal antibody rituximab for the treatment of B-cell chronic lymphocytic leukemia-associated pure red cell aplasia.
Pantelidou D; Tsatalas C; Margaritis D; Kaloutsi V; Spanoudakis E; Bourikas G
Hematol J; 2004; 5(6):546-7. PubMed ID: 15570303
[No Abstract] [Full Text] [Related]
12. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
[TBL] [Abstract][Full Text] [Related]
13. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.
Jourdan E; Topart D; Richard B; Jourdan J; Sotto A
Leuk Lymphoma; 2003 May; 44(5):889-90. PubMed ID: 12802933
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia.
Ghazal H
Blood; 2002 Feb; 99(3):1092-4. PubMed ID: 11807020
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.
Nishida H; Murase T; Ueno H; Park JW; Yano T; Ikeda Y
Leuk Res; 2006 Dec; 30(12):1589-90. PubMed ID: 16542723
[TBL] [Abstract][Full Text] [Related]
16. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.
Hegde UP; Wilson WH; White T; Cheson BD
Blood; 2002 Sep; 100(6):2260-2. PubMed ID: 12200396
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.
Zaja F; Vianelli N; Sperotto A; Patriarca F; Tani M; Marin L; Tiribelli M; Candoni A; Baccarani M; Fanin R
Leuk Lymphoma; 2003 Nov; 44(11):1951-5. PubMed ID: 14738149
[TBL] [Abstract][Full Text] [Related]
18. Local experience with the novel human anti-CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia.
Cheah CY; Carney DA; Lim SM; Januszewicz H; Scarlett J; Seymour JF
Intern Med J; 2012 Jul; 42(7):846-8. PubMed ID: 22805693
[No Abstract] [Full Text] [Related]
19. [Hematologic remission and disappearance of hemolytic anemia in chronic lymphocytic leukemia after therapy with 2-chlorodeoxyadenosine (2-CDA)].
Piatkowska-Jakubas B; Skotnicki AB
Acta Haematol Pol; 1993; 24(3):289-93. PubMed ID: 7902636
[TBL] [Abstract][Full Text] [Related]
20. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia.
Pamuk GE; Turgut B; Demir M; Tezcan F; Vural O
Am J Hematol; 2006 Aug; 81(8):631-3. PubMed ID: 16906592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
